Humacyte, Inc. announced plans to file an Investigational New Drug (IND) application with the FDA, aiming to conduct first-in-human clinical trials of its small-diameter acellular tissue engineered ...

– Positive preclinical results of the small-diameter ATEV were recently presented at The American Heart Association’s Scientific Sessions 2024 meeting – DURHAM, N.C., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ...

Shattuck Labs, Inc. has announced progress in its SL-325 program, with an Investigational New Drug (IND) filing expected in the third quarter of 2025. The company reported a cash balance of ...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...

SHANGHAI and SANTA BARBARA, Calif., Sept. 15, 2025 /PRNewswire/ --Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced today the successful submission of ...

BERKELEY, Calif., Sept. 24, 2025 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering continuous protein therapy for skin diseases, today announced the successful completion of a ...

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic ...

FibroBiologics (FBLG) announced the filing of a Phase 1/2 Investigational New Drug application with the U.S. Food and Drug Administration seeking regulatory clearance to initiate clinical trials of ...

Abpro Holdings Inc. and Celltrion Inc. have announced the submission of an IND application to the FDA for ABP-102 (CT-P72), a HER2 x CD3 T-cell engager. Pending clearance, a phase I trial in patients ...